At present, according to the 2021 Chinese Society of Clinical Oncology (CSCO) guidelines, the first-line of treatment for patients with BRAF-mutated advanced CRC is recommended to be FOLFOX/FOFIRI/XELOX ± bevacizumab for grade I, and FOLFOXIRI ± bevacizumab for grade II. The gene discussed is BRAF; the disease is colorectal carcinoma.